斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bionorica se, nemecko - expektoranciá - 94 - fytopharmaca

斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bionorica se, nemecko - expektoranciá s výnimkou kombinácií s antitusikami - 52 - expectorantia, mucolytica

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leukémia, myelogénna, chronická, bcr-abl pozitívna - antineoplastické činidlá - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

pierre fabre medicament - propranolol-hydrochloridu - hemangiom - beta-blokátory - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - viacnásobný myelóm - antineoplastické činidlá - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptiká, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systémový - imunosupresíva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bb pharma a.s., Česká republika - petidín - 65 - analgetica - anodyna

斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

laboratories thea - karteolol - 64 - ophthalmologica

斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - acetylcysteín - 52 - expectorantia, mucolytica